Bioneer

Bioneer EBIT per Share

The EBIT per Share of Bioneer (064550.KQ) as of Nov 7, 2026 is 490.33 KRW. In the previous year, EBIT per Share was -524.45 KRW — a change of -193.50% (higher).

EBIT per Share

490.33KRW

YoY

-193.50%

Last updated:

EBIT per Share of Bioneer is 2025 490.33 KRW. EBIT per Share of Bioneer was 2024 -524.45 KRW. It decreases by -193.50% higher compared to the previous year.

The Bioneer EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2018
-660.88 KRW
Jan 1, 2019
-422.61 KRW
Jan 1, 2020
4,173.60 KRW
Jan 1, 2021
1,825.20 KRW
Jan 1, 2023
32.04 KRW
Jan 1, 2024
-524.45 KRW
Jan 1, 2025
490.33 KRW
Jan 1, 2026 (e)
3,960.30 KRW
The Bioneer EBIT per Share history
YEAREBIT per ShareYoY
est3,960.30KRW+707.68%
490.33KRW-193.50%
-524.45KRW-1,736.92%
32.04KRW-98.24%
1,825.20KRW-56.27%
4,173.60KRW-1,087.59%
-422.61KRW-36.05%
-660.88KRW+28.32%
-515.02KRW-28.92%
-724.52KRW+133.52%
-310.26KRW-55.82%
-702.32KRW+26,872.39%
-2.60KRW-100.34%
760.84KRW-2,827.82%
-27.89KRW-85.09%
-187.11KRW-48.04%
-360.10KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioneer Stock analysis

What does Bioneer do? BIONEER Corp. generates revenue through the sale of biotechnological products, primarily DNA reagents, molecular diagnostic kits, and related services. The company offers DNA and RNA amplification products, Oligo synthesis, gene synthesis services, gene and protein expression, genomics services, and human and veterinary diagnostics kits. It also sells DNA extraction, amplification, and quantitative analysis devices, along with equipment and supplies for biotechnology research. These products are sold to domestic and international markets, including America, China, Japan, India, and Africa, where they serve research institutions, diagnostic laboratories, and healthcare providers. The firm's revenue streams include DNA reagents, molecular diagnostic kits, and DNA diagnostic devices, which are used by customers in the biotechnology, healthcare, and veterinary sectors. DNA amplification products and gene synthesis services are key offerings for research-focused clients, while human and veterinary diagnostics kits target healthcare and animal health markets. Equipment and supplies for biotechnology research are sold to academic and commercial laboratories globally. BIONEER Corp. focuses on developing and selling specialized biotechnology products, with a strong emphasis on DNA and RNA-related technologies. Its product portfolio includes reagents, kits, devices, and services that cater to both research and diagnostic applications. The company's international presence in key markets like America, China, and Japan drives its revenue, with a significant portion coming from the sale of diagnostic kits and DNA analysis equipment. Bioneer is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioneer stock

EBIT per Share of Bioneer is 490.33 KRW in 2025.

EBIT per Share of Bioneer changed from -524.45 KRW to 490.33 KRW, representing a -193.50% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Bioneer since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Bioneer

All Key Metrics — Bioneer